# A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Source: https://onco.cc/trials/nct06778031/  
OnCo record `nct06778031` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab rezetecan, Adebrelimab and SHR-8068 in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT06778031 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 54 participants planned, started 2025-02-26 and due to reach its primary completion in 2028-06. Interventions recorded: SHR-A1811, SHR-1316 and SHR-8068.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06778031
- Phase: 2
- Setting: An Open, Multicenter Phase II Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT06778031: https://clinicaltrials.gov/study/NCT06778031

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-8068](https://onco.cc/drugs/shr-8068/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06778031.json